The effect of deuterated PLK1 inhibitor on its safety and efficacy in vivo
{{output}}
Background: The FDA's approval of deutetrabenazine, the first deuterium-labeled drug, demonstrated an improved safety profile compared to its non-deuterated counterpart, tetrabenazine. While Polo-like kinase 1 (PLK1) inhibitors ... ...
